Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (101-110 of 426) with videos related to

Pageof 43
Sort By:
Frontiers in Oncology|September 5, 2022
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinomaMimma Rizzo, Luca Varnier, Gaetano Pezzicoli, et al.
Expert Review of Anticancer Therapy|November 28, 2012
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-scienceCamillo Porta, Roberto Sabbatini, Giuseppe Procopio, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative reviewValentina Poletto, Vittorio Rosti, Marco Biggiogera, et al.
Future Oncology (London, England)|May 31, 2013
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitorRoberto Sabbatini, Cinizia Ortega, Giuseppe Procopio, et al.
Future Oncology (London, England)|August 17, 2012
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinomaIlaria Imarisio, Chiara Paglino, Carlo Ganini, et al.
Oncology Reports|September 18, 2004
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patientsAndrea Sartore-Bianchi, Alessandra Soriani, Raffaella Mattioni, et al.
Cancer Treatment Reviews|February 19, 2021
Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?Annalisa Guida, Roberto Sabbatini, Lara Gibellini, et al.
European Urology Oncology|August 15, 2019
Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the EndFrancesco Massari, Vincenzo Di Nunno, Matteo Santoni, et al.
Nature Reviews. Nephrology|September 28, 2022
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injuryBen Sprangers, David E Leaf, Camillo Porta, et al.
Journal of Nephrology|October 18, 2018
Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelinesGiovanni M Frascà, Fabiana Brigante, Alessandro Volpe, et al.
Pageof 43

Showing results (101-110 of 426) with videos related to

Sort By:
Pageof 43
Frontiers in Oncology|September 5, 2022
IL-8 and its role as a potential biomarker of resistance to anti-angiogenic agents and immune checkpoint inhibitors in metastatic renal cell carcinomaMimma Rizzo, Luca Varnier, Gaetano Pezzicoli, et al.
Expert Review of Anticancer Therapy|November 28, 2012
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-scienceCamillo Porta, Roberto Sabbatini, Giuseppe Procopio, et al.
Critical Reviews in Oncology/Hematology|November 19, 2018
The role of endothelial colony forming cells in kidney cancer's pathogenesis, and in resistance to anti-VEGFR agents and mTOR inhibitors: A speculative reviewValentina Poletto, Vittorio Rosti, Marco Biggiogera, et al.
Future Oncology (London, England)|May 31, 2013
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitorRoberto Sabbatini, Cinizia Ortega, Giuseppe Procopio, et al.
Future Oncology (London, England)|August 17, 2012
The effect of sorafenib treatment on the diabetic status of patients with renal cell or hepatocellular carcinomaIlaria Imarisio, Chiara Paglino, Carlo Ganini, et al.
Oncology Reports|September 18, 2004
Low doses of subcutaneous interleukin-2 plus interferon-alpha do not induce thyroid function alterations in advanced renal cell carcinoma patientsAndrea Sartore-Bianchi, Alessandra Soriani, Raffaella Mattioni, et al.
Cancer Treatment Reviews|February 19, 2021
Finding predictive factors for immunotherapy in metastatic renal-cell carcinoma: What are we looking for?Annalisa Guida, Roberto Sabbatini, Lara Gibellini, et al.
European Urology Oncology|August 15, 2019
Re: Bimal Bhindi, E. Jason Abel, Laurence Albiges, et al. Systematic Review of the Role of Cytoreductive Nephrectomy in the Targeted Therapy Era and Beyond: An Individualized Approach to Metastatic Renal Cell Carcinoma. Eur Urol 2019;75:111-28: Cytoreductive Nephrectomy in the Targeted Therapy Era: This is Not the EndFrancesco Massari, Vincenzo Di Nunno, Matteo Santoni, et al.
Nature Reviews. Nephrology|September 28, 2022
Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injuryBen Sprangers, David E Leaf, Camillo Porta, et al.
Journal of Nephrology|October 18, 2018
Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelinesGiovanni M Frascà, Fabiana Brigante, Alessandro Volpe, et al.
Pageof 43